- TreeFrog Therapeutics and Invetech started their collaboration in 2019 to industrialize TreeFrog’s stem cell encapsulation technology to enable the mass production of hPSC -derived cell therapies in industrial bioreactors, with best-in-class cell quality and low production costs.
- Invetech delivered a beta encapsulation system with a throughput of 1,000 stem cell capsules per second to TreeFrog Therapeutics in the second quarter of 2020.
- The strategic partnership aims to develop a GMP-compliant encapsulation device by the end of 2022 to support TreeFrog Therapeutics’ in-house and partnered cell therapy programs.
Bordeaux, France and San Diego, California, USA, 7 October 2020 – TreeFrog Therapeutics, a French biotech leveraging a unique cell manufacturing technology to advance a pipeline of cell therapies with mass-market potential, and Invetech, a global leader in the development and production of automated manufacturing solutions for cell and advanced therapies, today announced a strategic partnership to develop a GMP-compliant device for high-throughput stem cell encapsulation by the end of 2022.
Since January 2019, TreeFrog Therapeutics has been collaborating with Invetech to turn its R&D encapsulation set-up into an automated single-use device for industrial bioproduction. “Our C-StemTM technology bridges stem cell biology and biophysics,” explained Kevin Alessandri, CEO and CTO of TreeFrog Therapeutics. “We found in Invetech a team eager to confront a new technology, with strong execution capacities, supported by a step-by-step methodology to de-risk the project. As a matter of fact, they managed to deliver the prototype in time in April 2020, right in the middle of the COVID crisis.”